{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone+%28drug%29&page=2",
    "query": {
      "intervention": "Spironolactone (drug)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 105,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone+%28drug%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone+%28drug%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T04:32:43.471Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02354352",
      "title": "Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Eplerenone",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "7 Years and older · Male only"
      },
      "enrollment_count": 52,
      "start_date": "2015-03-20",
      "completion_date": "2018-05",
      "has_results": true,
      "last_update_posted_date": "2019-10-07",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02354352"
    },
    {
      "nct_id": "NCT01598740",
      "title": "Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "CLP",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sorbent Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2012-06",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2013-07-19",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 1,
      "location_summary": "Tustin, California",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01598740"
    },
    {
      "nct_id": "NCT02169089",
      "title": "Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "41 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "41 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2016-01",
      "completion_date": "2022-04-29",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02169089"
    },
    {
      "nct_id": "NCT04676646",
      "title": "Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperkalaemia",
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Sodium zirconium cyclosilicate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 366,
      "start_date": "2021-03-08",
      "completion_date": "2024-07-15",
      "has_results": true,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 12,
      "location_summary": "Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Hazel Crest",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676646"
    },
    {
      "nct_id": "NCT07015671",
      "title": "Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bioequivalence Study in Healthy Subjects",
        "PK/PD"
      ],
      "interventions": [
        {
          "name": "10 mg Torsemide tablet",
          "type": "DRUG"
        },
        {
          "name": "25 mg Aldactone (Spironolactone) tablet",
          "type": "DRUG"
        },
        {
          "name": "FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarfez Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-07-01",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 1,
      "location_summary": "Vienna, Virginia",
      "locations": [
        {
          "city": "Vienna",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07015671"
    },
    {
      "nct_id": "NCT00206232",
      "title": "Novel Treatment for Diastolic Heart Failure in Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2004-07",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-02-18",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206232"
    },
    {
      "nct_id": "NCT01103245",
      "title": "Aldosterone and the Metabolic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolic Diseases",
        "Diabetes Mellitus",
        "Endocrine System Diseases",
        "Glucose Metabolism Disorders"
      ],
      "interventions": [
        {
          "name": "Hydrochlorothiazide (HCTZ)",
          "type": "DRUG"
        },
        {
          "name": "Aliskiren 150 mg (ALI 150)",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone (SPL 25)",
          "type": "DRUG"
        },
        {
          "name": "Aliskiren 300 mg (ALI 300)",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone 50 mg (SPL 50)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 69,
      "start_date": "2010-03",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-05",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01103245"
    },
    {
      "nct_id": "NCT01853553",
      "title": "Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADPKD"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Sugar pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "20 Years to 55 Years"
      },
      "enrollment_count": 61,
      "start_date": "2013-07",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2019-08-20",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853553"
    },
    {
      "nct_id": "NCT06004830",
      "title": "Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder",
        "Hiv"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-11-06",
      "completion_date": "2026-01-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06004830"
    },
    {
      "nct_id": "NCT00879060",
      "title": "Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Myocardial Fibrosis",
        "Hypertrophic Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 53,
      "start_date": "2007-11",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2021-04-27",
      "last_synced_at": "2026-10-05T04:32:43.471Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00879060"
    }
  ]
}